753 related articles for article (PubMed ID: 26373566)
1. Comparison of Lupus Nephritis Induction Treatments in a Hispanic Population: A Single-center Cohort Analysis.
Mejía-Vilet JM; Arreola-Guerra JM; Córdova-Sánchez BM; Morales-Buenrostro LE; Uribe-Uribe NO; Correa-Rotter R
J Rheumatol; 2015 Nov; 42(11):2082-91. PubMed ID: 26373566
[TBL] [Abstract][Full Text] [Related]
2. Renal flare prediction and prognosis in lupus nephritis Hispanic patients.
Mejía-Vilet JM; Córdova-Sánchez BM; Arreola-Guerra JM; Morales-Buenrostro LE; Uribe-Uribe NO; Correa-Rotter R
Lupus; 2016 Mar; 25(3):315-24. PubMed ID: 26405028
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes of lupus nephritis treated with regimens based on cyclophosphamide and mycophenolate mofetil.
Prasad N; Kurian J; Agarwal V; Bhadauria D; Behera M; Yacha M; Kushwaha R; Agrawal V; Jain M; Gupta A
Lupus; 2020 Jul; 29(8):845-853. PubMed ID: 32437258
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolate mofetil versus azathioprine in the maintenance therapy of lupus nephritis.
Sahin GM; Sahin S; Kiziltas S; Masatlioglu S; Oguz F; Ergin H
Ren Fail; 2008; 30(9):865-9. PubMed ID: 18925525
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppressive treatment for pure membranous lupus nephropathy in a Hispanic population.
Mejía-Vilet JM; Córdova-Sánchez BM; Uribe-Uribe NO; Correa-Rotter R
Clin Rheumatol; 2016 Sep; 35(9):2219-27. PubMed ID: 27475791
[TBL] [Abstract][Full Text] [Related]
6. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide.
Contreras G; Tozman E; Nahar N; Metz D
Lupus; 2005; 14 Suppl 1():s33-8. PubMed ID: 15803929
[TBL] [Abstract][Full Text] [Related]
7. Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis.
Li X; Ren H; Zhang Q; Zhang W; Wu X; Xu Y; Shen P; Chen N
Nephrol Dial Transplant; 2012 Apr; 27(4):1467-72. PubMed ID: 21917733
[TBL] [Abstract][Full Text] [Related]
8. Repeat kidney biopsies fail to detect differences between azathioprine and mycophenolate mofetil maintenance therapy for lupus nephritis: data from the MAINTAIN Nephritis Trial.
Stoenoiu MS; Aydin S; Tektonidou M; Ravelingien I; le Guern V; Fiehn C; Remy P; Delahousse M; Petera P; Quémeneur T; Vasconcelos C; D'Cruz D; Gilboe IM; Jadoul M; Karras A; Depresseux G; Guillevin L; Cervera R; Cosyns JP; Houssiau FA;
Nephrol Dial Transplant; 2012 May; 27(5):1924-30. PubMed ID: 22110048
[TBL] [Abstract][Full Text] [Related]
9. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up.
Mok CC; Ying KY; Yim CW; Siu YP; Tong KH; To CH; Ng WL
Ann Rheum Dis; 2016 Jan; 75(1):30-6. PubMed ID: 25550339
[TBL] [Abstract][Full Text] [Related]
10. Sequential therapies for proliferative lupus nephritis.
Contreras G; Pardo V; Leclercq B; Lenz O; Tozman E; O'Nan P; Roth D
N Engl J Med; 2004 Mar; 350(10):971-80. PubMed ID: 14999109
[TBL] [Abstract][Full Text] [Related]
11. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial.
Houssiau FA; D'Cruz D; Sangle S; Remy P; Vasconcelos C; Petrovic R; Fiehn C; de Ramon Garrido E; Gilboe IM; Tektonidou M; Blockmans D; Ravelingien I; le Guern V; Depresseux G; Guillevin L; Cervera R;
Ann Rheum Dis; 2010 Dec; 69(12):2083-9. PubMed ID: 20833738
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive treatment for proliferative lupus nephritis.
Tunnicliffe DJ; Palmer SC; Henderson L; Masson P; Craig JC; Tong A; Singh-Grewal D; Flanc RS; Roberts MA; Webster AC; Strippoli GF
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD002922. PubMed ID: 29957821
[TBL] [Abstract][Full Text] [Related]
13. Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial.
Kamanamool N; Ingsathit A; Rattanasiri S; Ngamjanyaporn P; Kasitanont N; Chawanasuntorapoj R; Pichaiwong W; Anutrakulchai S; Sangthawan P; Ophascharoensuk V; Avihingsanon Y; Sumethkul V
Lupus; 2018 Apr; 27(4):647-656. PubMed ID: 29105558
[TBL] [Abstract][Full Text] [Related]
14. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial.
Grootscholten C; Ligtenberg G; Hagen EC; van den Wall Bake AW; de Glas-Vos JW; Bijl M; Assmann KJ; Bruijn JA; Weening JJ; van Houwelingen HC; Derksen RH; Berden JH;
Kidney Int; 2006 Aug; 70(4):732-42. PubMed ID: 16820790
[TBL] [Abstract][Full Text] [Related]
15. Mycophenolate mofetil versus azathioprine as maintenance therapy for lupus nephritis: a meta-analysis.
Feng L; Deng J; Huo DM; Wu QY; Liao YH
Nephrology (Carlton); 2013 Feb; 18(2):104-10. PubMed ID: 23113811
[TBL] [Abstract][Full Text] [Related]
16. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.
Appel GB; Contreras G; Dooley MA; Ginzler EM; Isenberg D; Jayne D; Li LS; Mysler E; Sánchez-Guerrero J; Solomons N; Wofsy D;
J Am Soc Nephrol; 2009 May; 20(5):1103-12. PubMed ID: 19369404
[TBL] [Abstract][Full Text] [Related]
17. Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide.
Wang J; Hu W; Xie H; Zhang H; Chen H; Zeng C; Liu Z; Li L
Lupus; 2007; 16(9):707-12. PubMed ID: 17728363
[TBL] [Abstract][Full Text] [Related]
18. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis.
Ong LM; Hooi LS; Lim TO; Goh BL; Ahmad G; Ghazalli R; Teo SM; Wong HS; Tan SY; Shaariah W; Tan CC; Morad Z
Nephrology (Carlton); 2005 Oct; 10(5):504-10. PubMed ID: 16221103
[TBL] [Abstract][Full Text] [Related]
19. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis.
Chan TM; Tse KC; Tang CS; Mok MY; Li FK;
J Am Soc Nephrol; 2005 Apr; 16(4):1076-84. PubMed ID: 15728784
[TBL] [Abstract][Full Text] [Related]
20. Outcome and predictors of renal survival in patients with lupus nephritis: Comparison between cyclophosphamide and mycophenolate mofetil.
Joo YB; Kang YM; Kim HA; Suh CH; Kim TJ; Park YW; Lee J; Lee JH; Yoo DH; Bae SC; Lee HS; Bang SY
Int J Rheum Dis; 2018 May; 21(5):1031-1039. PubMed ID: 29611341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
